Calcivis, an Edinburgh, Scotland, UK-based medical devices company focused on innovating the management of tooth decay and enabling preventive dentistry, secured a new equity funding round of undisclosed amount.
Backers included existing investors Archangel Investors, the Scottish Investment Bank, and Julz.
The company intends to use the funds to support commercialization steps including UK launch to dental practices and Pre-Market Authorisation (PMA) filing with the FDA before the end of 2017 in anticipation of early 2019 launch in the US.
Led by Adam Christie, CEO, Calcivis provides an imaging system that enables the assessment and management of demineralization associated with dental caries and erosion.
The imaging system will allow the real-time visualisation of calcium ions released from demineralizing tooth surfaces, in routine dental practice. The resulting images provide a focus for discussion with patients and enable the development of a preventive treatment plan in line with dental best practice.
The Calcivis imaging system has gained a CE Mark in Europe and will be launched in the UK later this year.
Launched in 2012, the company has been funded by Archangel Investors Limited and the Scottish Investment Bank, the investment arm of Scottish Enterprise and has raised equity and grant funding totalling over £9m since its inception.
FinSMEs
04/10/2017